Dernières nouvelles pour CNS Pharma (NASDAQ:CNSP) Stock

CNS Pharmaceuticals

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

CNS Pharmaceuticals Inc

<p>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) reported quarterly sales of $1.200 million which missed the analyst consensus estimate of $1.796 million by 33.18 percent.</p>


Earnings

Earnings Misses

News

VNRX

VolitionRX FY Sales $1.200M Miss $1.796M Estimate

Earnings Beats

LPRO

Open Lending Q4 2024 GAAP EPS $1.21 Beats $0.02 Estimate, Sales $(56.90M) Miss $23.65M Estimate

Biotech

General

CNTB

Connect Biopharma Reports Data From Global Phase 2 Trial Of Rademikibart In Patients With Moderate-To-Severe Uncontrolled Asthma

<p>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.16) by 56.25 percent. This is a 72 percent increase over losses of $(0.25) per share from the same period last year.</p>


TLPH

Talphera Q4 2024 GAAP EPS $(0.07) Beats $(0.16) Estimate

Guidance

SONM

Sonim Technologies FY24 EPS ($7.13) Down From ($0.02) YoY; Revenue $58.29M Down From $93.63M YoY.

<p>Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) reported quarterly losses of $(0.29) per share. This is a 81.88 percent increase over losses of $(1.60) per share from the same period last year.  The company reported quarterly sales of $20.23 million which beat the analyst consensus estimate of $17.40 million by 16.24 percent.  This is a 28.82 percent increase over sales of $15.70 million the same period last year.</p>


Spruce Power Holding Corporation Class A Common Stock

SPRU

Spruce Power Holding Q4 2024 GAAP EPS $(0.29) Up From $(1.60) YoY, Sales $20.23M Beat $17.40M Estimate

<p>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.25) by 8 percent. This is unchanged from the same period last year.</p>


RANI

Rani Therapeutics Hldgs Q4 2024 GAAP EPS $(0.27) Misses $(0.25) Estimate

Management

Open Lending Appoints Jessica Buss As CEO And Michelle Glasl As COO, Effective Immediately

<p>Tucker served as interim CEO since February 2025 after being hired as chief financial officer for the company in November 2024, which followed a previous tenure as CFO of Jack in the Box from March 2018 to September 2020.</p>
<p><br />&nbsp;</p>


JACK

Jack In The Box Names Lance Tucker As CEO; Tucker Served As Interim CEO Since February 2025

<p>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.82) by 23.17 percent. This is unchanged from the same period last year.</p>


OMER

Omeros Q4 2024 GAAP EPS $(0.63) Beats $(0.82) Estimate

<p>Construction is scheduled to begin in Summer 2025 with substantial completion anticipated in Spring 2030.</p>
<p><br />&nbsp;</p>


Contracts

Fluor Secures Construction Contract For The State Highway 6 Project In College Station, Texas; To Recognize The $671M Bid-Build Contract In Q1 Of 2025

RCAT

Red Cat Holdings 2024 Transition Period EPS $(0.57); Revenue $4.9M

GDEV

GDEV Q4 Revenue $98M Down From $109M QoQ.

<p>TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat individuals with achondroplasia by providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle.</p>


ASND

Ascendis Submits New Drug Application To FDA For TransCon CNP For Treatment Of Children With Achondroplasia.

<p>In the last three months, 8 analysts have published ratings on The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $132.5, along with a high estimate of $140.00 and a low estimate of $125.00. This current average reflects an increase of 1.44% from the previous average price target of $130.62. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451282_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive The Hartford Insurance Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Paul Newsome</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$126.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to The Hartford Insurance Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of The Hartford Insurance Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of The Hartford Insurance Gr's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of The Hartford Insurance Gr's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HIG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on The Hartford Insurance Gr analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind The Hartford Insurance Gr</h2>
<p>The Hartford Insurance Group Inc. provides property and casualty insurance, group benefits, and mutual funds. The company is widely recognized for its service excellence, sustainability practices, trust, and integrity. The Company currently conducts business principally in five reportable segments including Business Insurance, Personal Insurance, Property &amp; Casualty Other Operations, Employee Benefits, and Hartford Funds, as well as a Corporate category. The company generates a majority of its revenue from Business Insurance.</p>
<h3>The Hartford Insurance Gr: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> The Hartford Insurance Gr's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>7.54%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> The Hartford Insurance Gr's net margin is impressive, surpassing industry averages. With a net margin of <strong>12.47%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The Hartford Insurance Gr's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.17%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The Hartford Insurance Gr's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.05%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.27</strong>, The Hartford Insurance Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Assessing The Hartford Insurance Gr: Insights From 8 Financial Analysts

<p>During the last three months, 5 analysts shared their evaluations of Snap-on (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $370.0, along with a high estimate of $400.00 and a low estimate of $350.00. This upward trend is evident, with the current average reflecting a 2.42% increase from the previous average price target of $361.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451268_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Snap-on among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macgregor</td>
<td>Longbow Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$400.00</td>
<td>-</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$390.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Snap-on. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Snap-on compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Snap-on's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Snap-on's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Snap-on analyst ratings.</strong></a></p>
<h2>Discovering Snap-on: A Closer Look</h2>
<p>Snap-on manufactures premium tools and software for repair professionals. Hand tools are sold through a franchisee-operated mobile van network that serve auto technicians who purchase tools at their own expense. A unique element of its business model is that franchisees bear significant risk, as they must invest in the mobile van, inventory, and software. At the same time, franchisees extend personal credit directly to technicians on an individual tool basis. Snap-on currently operates three segments: repair systems and information, commercial and industrial, and tools. Its finance arm provides financing to franchisees to run their operations, which includes offering loans and leases for mobile vans.</p>
<h3>Snap-on: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Snap-on's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>0.18%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Snap-on's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>21.53%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Snap-on's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>4.75%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>3.26%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.24</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Snap-on: Insights From 5 Analyst Reviews

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Home Depot</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HD, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Home Depot.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 28% bullish and 50%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $119,477, and 10 are calls, for a total amount of $1,564,142.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $415.0 for Home Depot, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Home Depot options trades today is 484.31 with a total volume of 1,809.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Home Depot's big money trades within a strike price range of $200.0 to $415.0 over the last 30 days.</p>
<h3>Home Depot Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451267_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$31.1</td>
<td>$29.6</td>
<td>$31.1</td>
<td>$380.00</td>
<td>$622.0K</td>
<td>51</td>
<td align="right">200</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$3.95</td>
<td>$3.85</td>
<td>$3.9</td>
<td>$410.00</td>
<td>$361.9K</td>
<td>1.7K</td>
<td align="right">937</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$25.25</td>
<td>$25.1</td>
<td>$25.25</td>
<td>$350.00</td>
<td>$154.0K</td>
<td>186</td>
<td align="right">65</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$3.65</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$365.00</td>
<td>$123.6K</td>
<td>316</td>
<td align="right">390</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$167.25</td>
<td>$163.3</td>
<td>$165.18</td>
<td>$200.00</td>
<td>$82.5K</td>
<td>12</td>
<td align="right">11</td>
</tr>
</tbody>
</table>
</p>
<h3>About Home Depot</h3>
<p>Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the US, Canada, and Mexico. Its stores offer building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of Interline Brands in 2015 allowed Home Depot to enter the MRO business, which has been expanded through the tie-up with HD Supply (2020). The additions of the Company Store brought textiles to the lineup, and the 2024 tie-up with SRS will help grow professional demand in roofing, pool and landscaping projects.</p>
<p>Following our analysis of the options activities associated with Home Depot, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Home Depot</h3>
<ul>
<li>With a volume of 2,316,777, the price of HD is up 2.71% at $367.85. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 43 days.</li>
</ul>
<h3>What The Experts Say On Home Depot</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $418.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Home Depot, targeting a price of $418. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Home Depot with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

What the Options Market Tells Us About Home Depot

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Accenture</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ACN, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Accenture.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 35% bullish and 50%, bearish.</p>
<p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $382,190, and 5 are calls, for a total amount of $183,546.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $300.0 to $350.0 for Accenture over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Accenture's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Accenture's whale trades within a strike price range from $300.0 to $350.0 in the last 30 days. </p>
<h3>Accenture Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451262_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$17.6</td>
<td>$17.4</td>
<td>$17.5</td>
<td>$300.00</td>
<td>$61.2K</td>
<td align="right">358</td>
<td align="right">101</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$17.6</td>
<td>$17.3</td>
<td>$17.6</td>
<td>$300.00</td>
<td>$52.8K</td>
<td align="right">358</td>
<td align="right">52</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$28.3</td>
<td>$25.7</td>
<td>$27.9</td>
<td>$340.00</td>
<td>$50.2K</td>
<td align="right">7</td>
<td align="right">18</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$9.9</td>
<td>$9.6</td>
<td>$9.9</td>
<td>$310.00</td>
<td>$48.5K</td>
<td align="right">149</td>
<td align="right">97</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/04/25</td>
<td>$1.45</td>
<td>$1.1</td>
<td>$1.4</td>
<td>$315.00</td>
<td>$46.7K</td>
<td align="right">59</td>
<td align="right">912</td>
</tr>
</tbody>
</table>
</p>
<h3>About Accenture</h3>
<p>Accenture is a leading global IT services firm that provides consulting, strategy, and technology and operational services. These services run the gamut from aiding enterprises with digital transformation to procurement services to software system integration. The company provides its IT offerings to a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture employs just under 500,000 people throughout 200 cities in 51 countries.</p>
<p>Following our analysis of the options activities associated with Accenture, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Accenture</h3>
<ul>
<li>Trading volume stands at 2,992,244, with ACN's price up by 2.75%, positioned at $312.71.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 81 days.</li>
</ul>
<h3>What Analysts Are Saying About Accenture</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $383.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Accenture, which currently sits at a price target of $372.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on Accenture, maintaining a target price of $390.<br />
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Accenture, maintaining a target price of $396.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Accenture, targeting a price of $387.<br />
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Market Perform rating on Accenture with a target price of $370. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Accenture with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


What the Options Market Tells Us About Accenture

<p>In the last three months, 13 analysts have published ratings on Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $19.4, a high estimate of $22.00, and a low estimate of $16.00. Marking an increase of 4.75%, the current average surpasses the previous average price target of $18.52. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451258_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Invesco by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Etienne Ricard</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.75</td>
<td>$19.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$19.50</td>
<td>$17.00</td>
</tr>
<tr>
<td>Stephen Biggar</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$17.00</td>
<td>$17.50</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$19.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Invesco. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Invesco compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Invesco's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Invesco's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IVZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Invesco analyst ratings.</strong></a></p>
<h2>About Invesco</h2>
<p>Invesco provides investment-management services to retail (68% of managed assets) and institutional (32%) clients. At the end of October 2024, the firm had $1.792 trillion in assets under management spread among its equity (58% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (10%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's us retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 29% of its AUM sourced from Europe, Africa, and the Middle East (14%) and Asia (15%).</p>
<h3>Key Indicators: Invesco's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Invesco's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>12.71%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Invesco's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>13.14%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.97%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Invesco's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.77%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Invesco's debt-to-equity ratio is below the industry average at <strong>0.72</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Invesco: Insights From 13 Analyst Reviews

<p>Deep-pocketed investors have adopted a bullish approach towards Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MSFT usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 248 extraordinary options activities for Microsoft. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 43% leaning bullish and 39% bearish. Among these notable options, 129 are puts, totaling $9,995,941, and 119 are calls, amounting to $8,253,185.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $115.0 to $530.0 for Microsoft over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Microsoft's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Microsoft's whale activity within a strike price range from $115.0 to $530.0 in the last 30 days. </p>
<h3>Microsoft Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451257_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MSFT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$14.65</td>
<td>$14.55</td>
<td>$14.65</td>
<td>$365.00</td>
<td>$366.2K</td>
<td>3.5K</td>
<td>1.2K</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/04/25</td>
<td>$0.8</td>
<td>$0.75</td>
<td>$0.8</td>
<td>$390.00</td>
<td>$271.7K</td>
<td>3.3K</td>
<td>12.7K</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$19.45</td>
<td>$19.4</td>
<td>$19.4</td>
<td>$375.00</td>
<td>$193.9K</td>
<td>2.1K</td>
<td>118</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$19.4</td>
<td>$19.25</td>
<td>$19.35</td>
<td>$375.00</td>
<td>$193.5K</td>
<td>2.1K</td>
<td>418</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$19.45</td>
<td>$19.35</td>
<td>$19.35</td>
<td>$375.00</td>
<td>$193.5K</td>
<td>2.1K</td>
<td>318</td>
</tr>
</tbody>
</table>
</p>
<h3>About Microsoft</h3>
<p>Microsoft develops and licenses consumer and enterprise software. It is known for its Windows operating systems and Office productivity suite. The company is organized into three equally sized broad segments: productivity and business processes (legacy Microsoft Office, cloud-based Office 365, Exchange, SharePoint, Skype, LinkedIn, Dynamics), intelligence cloud (infrastructure- and platform-as-a-service offerings Azure, Windows Server OS, SQL Server), and more personal computing (Windows Client, Xbox, Bing search, display advertising, and Surface laptops, tablets, and desktops).</p>
<p>In light of the recent options history for Microsoft, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Microsoft's Current Market Status</h3>
<ul>
<li>With a trading volume of 18,083,669, the price of MSFT is down by -1.14%, reaching $374.49.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 24 days from now.</li>
</ul>
<h3>Expert Opinions on Microsoft</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $518.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Microsoft, which currently sits at a price target of $475.<br />
&#x2A; An analyst from Tigress Financial persists with their Buy rating on Microsoft, maintaining a target price of $595.<br />
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $550.<br />
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Microsoft, targeting a price of $500.<br />
&#x2A; Reflecting concerns, an analyst from Scotiabank lowers its rating to Sector Outperform with a new price target of $470.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Microsoft options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


MSFT

This Is What Whales Are Betting On Microsoft

Press Releases

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Events

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals Announces Reverse Stock Split

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

AKTX

AMIX

AREC

CNSP

HURA

NVNO

OTLK

PALI

Akanda

Artelo Biosciences

CNS Pharma

Enveric Biosciences

Eyenovia

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

Jaguar Health

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SenesTech

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

Virpax Pharmaceuticals, Inc. - Common Stock

Comments

CNS Pharma

Actualités

Dernières nouvelles pour CNS Pharma (NASDAQ:CNSP) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL